Increasing instances of genetic predisposition, rising organ transplantation procedures, prevalence of HIV AIDS, tourism to the countries with KS cases, innovation of chemotherapy drugs, rising number of regional vendors, government initiatives, etc are strengthening underlying demand of Kaposi Sarcoma market.
“Global Kaposi Sarcoma Market Outlook 2024”
According to Goldstein Research, global Kaposi sarcoma market has increased at a CAGR of 2.25% over the forecast period that will exhibit valuation of USD 0.15 billion by 2024 rising from USD 0.11 billion in 2016.
Chemotherapy is expected to exhibit growth at the most promising pace due to the high treatment cost and the high preference given to the treatment method by immune-competent patients while biopsy is the first step to diagnose the Kaposi sarcoma and CT scan is usually done to determine if the cancer has spread to the lymph nodes, liver and lungs both contributing the modest share in Kaposi sarcoma market.
Geographically, North America is the dominating region in global Kaposi sarcoma market put down to the presence of some of the world’s leading vendors in the field and the rising costs of drugs.
Kaposi Sarcoma: Don’t Miss the Diagnosis
In most of the scenarios, the best initial preventive approach to treat KS may be to lower the viral load and boost up the immune system by HIV treatment. Kaposi's sarcoma is seen less since the introduction of effective HIV treatment and often improves or disappears once HIV treatment is started. HHV-8 and Kaposi's sarcoma both are more recurrent among HIV-positive gay or bisexual men with histories of multiple sexually transmitted diseases and exposure to both prescription and recreational drugs, women who were infected with HIV through sex with bisexual men, and people from African communities, than other groups of people with HIV.
“Global Kaposi Sarcoma Market Outlook 2024” contains detailed overview of the global Kaposi sarcoma market in terms of market segmentation by diagnosis, treatment and end user.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, market challenges, risk analysis, market attractiveness, BPS (Base Point Scale) analysis, Porter’s five force model and SWOT analysis.
Global Kaposi Sarcoma market report also provides competitive outlook for some of the major players which includes profiling of companies such as Johnson & Johnson, Merck & Co., Inc., Bristol Myers Squibb, Hoffman-La Roche, Inc., Pfizer, Inc., GlaxoSmithKline plc, and Eli Lilly and Co, etc. The company profiles include business strategy, geographical revenue distribution, major information of the companies which encompasses business outlook, products, services and industries catered, financial analysis of the company and recent developments.
Overall, the report represents comprehensive synopsis on the global Kaposi sarcoma market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Send Us Sample Request
Based in the US, Goldstein Research currently has a strong presence in the American and Asian countries. In the next five years, we strive to expand our reach to 50+ nations spanning across Europe, Asia and parts of the Middle East and Africa. We strive to realize a strong brand presence globally through our quality research and forecasting solutions.
Our mission is simple: to develop insightful business solutions, help our clients make powerful future decisions to keep them well ahead of the game which is the market, and leave a mark across businesses and communities through our well-defined ideas and clear cut forecasts. Backed up by reliable research and impactful statistics, our business solutions empower our clients to grow at a fast pace despite unsettling fluctuations in the market. We believe in vigorous examination of the current market scenario and build around creative ideas and approaches that are most suitable to our clients’ needs and business agenda.